company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8290000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8290000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1516000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1516000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6774000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2842000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2403000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,372000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5617000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1157000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,86000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,86000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1243000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-37000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1280000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1280000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1280000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,27896889.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28438118.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q2,2010-04-01,2010-06-30,2011-08-05 07:05:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7246000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7246000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7246000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2054000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4072000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6503000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,743000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,156000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,156000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,899000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2285000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3184000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3184000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3184000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28003453.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28466532.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28900000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2010.0,Q3,2010-07-01,2010-09-30,2011-11-07 07:00:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7501000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7501000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7501000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2858000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4267000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,369000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7494000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,7000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,135000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,135000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,142000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,136000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,136000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,136000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28101418.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28936835.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 07:06:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2572000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5999000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,372000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8943000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1513000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,121000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,121000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1392000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-51000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1341000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1341000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1341000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28103441.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28103441.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26800000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q2,2011-04-01,2011-06-30,2012-08-03 07:01:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7969000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7969000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7969000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2711000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8174000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11262000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3293000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,106000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,106000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3187000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-113000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3074000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3074000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3074000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28107363.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28107363.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,27900000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 07:02:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8370000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8370000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8370000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3345000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10556000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14278000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5908000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,99000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,99000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5809000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-286000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5523000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5523000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5523000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28106831.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28106831.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8141000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8141000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8141000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3909000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12180000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,369000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16458000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8317000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,355000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,355000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7962000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7962000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7962000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7962000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q1,2012-01-01,2012-03-31,2013-05-10 06:57:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8378000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8378000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8378000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3601000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12490000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,372000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16463000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8085000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,78000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,78000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8007000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8007000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8007000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8007000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q2,2012-04-01,2012-06-30,2013-07-31 07:08:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8288000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8288000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8288000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3147000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10159000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13683000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5395000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,69000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,69000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5326000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5326000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5326000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5326000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28226743.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 06:57:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7920000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7920000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,129000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,129000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7791000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3860000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10935000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15172000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7381000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,59000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,59000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7322000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7322000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7322000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7322000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28228409.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28228409.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28300000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8068000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8068000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8068000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4153000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8111000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,369000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12633000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4565000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,46000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,46000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4519000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4519000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4519000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4519000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28345555.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 07:01:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8319000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8319000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8319000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5260000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6100000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,372000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11732000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3413000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,30000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,30000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3383000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3383000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3383000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3383000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28377254.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q2,2013-04-01,2013-06-30,2014-08-08 07:01:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8709000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8709000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8709000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5741000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8022000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14140000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5431000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,25000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5406000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5406000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5406000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5406000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,31800000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,31800000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,31332993.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q3,2013-07-01,2013-09-30,2014-10-27 07:12:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,8783000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,8783000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8783000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9928000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6269000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,377000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16574000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7791000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,44000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,44000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7747000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7747000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7747000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7747000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,30351353.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,30351353.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30500000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9143000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9143000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9143000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27893000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7263000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,565000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35721000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26578000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,45000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,45000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26533000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26533000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26533000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26533000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.79
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.79
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33678706.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 16:32:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.79
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10862000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10862000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,198000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,198000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10664000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28139000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3514000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,617000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32270000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21606000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,31000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,31000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21575000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21575000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21575000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21575000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,33700000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,33700000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33874625.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q2,2014-04-01,2014-06-30,2015-07-31 07:01:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14782000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14782000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,703000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,703000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14079000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11290000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3701000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,536000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15527000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1448000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,22000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,22000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1426000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1426000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1426000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1426000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35700000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35700000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.04
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,33886845.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q3,2014-07-01,2014-09-30,2015-11-04 07:02:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15370000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15370000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,682000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,682000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14688000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,17322000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4752000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,536000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-77616000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-55006000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,69694000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,26000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,26000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,69720000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,69720000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,69720000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,69720000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,34774163.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36686723.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.02
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,34800000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22150000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22150000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5015000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5015000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17135000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18806000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4478000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,4144000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27428000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10293000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,72000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,72000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10221000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10221000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10221000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10221000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41744948.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q1,2015-01-01,2015-03-31,2016-05-05 07:02:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,27582000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,27582000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5766000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5766000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21816000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18386000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5946000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2942000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27274000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5458000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,72000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,72000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5386000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5386000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5386000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5386000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41991578.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 07:02:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28344000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,28344000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6510000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6510000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21834000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18458000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9974000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2943000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31375000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9541000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,80000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,80000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9461000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9461000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9461000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9461000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42435405.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q3,2015-07-01,2015-09-30,2016-11-03 07:01:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,31849000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,31849000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,25678000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28881000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8747000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2943000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,40571000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14893000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,96000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14797000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14797000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14797000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14797000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42250254.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.35
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42250254.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.35
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.35
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33262000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33262000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5956000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5956000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27306000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,29290000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7548000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2943000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39781000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12475000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,117000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,117000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12358000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12358000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12358000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12358000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42600000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43104462.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q1,2016-01-01,2016-03-31,2017-05-03 07:03:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36029000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36029000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6494000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6494000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,29535000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,24682000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6700000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2942000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34324000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4789000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4618000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4618000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4618000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4618000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43202751.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q2,2016-04-01,2016-06-30,2017-08-03 07:02:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.11
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,38482000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,38482000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6990000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6990000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,31492000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,21908000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7294000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2943000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32145000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-653000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,223000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,223000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-430000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43515404.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2016.0,Q3,2016-07-01,2016-09-30,2017-11-08 07:02:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,37415000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,37415000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4003000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4003000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,33412000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30297000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10567000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,454000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41318000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7906000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,280000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,280000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7626000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,19000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7645000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7645000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7645000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44398359.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44398359.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45000000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q1,2017-01-01,2017-03-31,2018-05-02 17:03:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.17
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,42056000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,42056000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4529000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4529000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37527000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31371000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7648000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,432000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39451000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1924000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,397000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,397000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1527000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1534000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1534000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1534000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44718597.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44718597.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51100000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q2,2017-04-01,2017-06-30,2018-08-02 07:01:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,41336000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,41336000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4525000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4525000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36811000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31124000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10178000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,432000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41734000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4923000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,396000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,396000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4527000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4550000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4550000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4550000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44885287.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44885287.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,45500000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q3,2017-07-01,2017-09-30,2018-11-07 17:08:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,44276000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,44276000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4791000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4791000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,39485000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31049000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10154000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,432000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41635000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2150000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,399000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,399000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1751000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,87000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1838000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1838000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1838000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,44735146.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44735146.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,44500000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43592000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43592000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4560000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4560000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,39032000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26822000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9416000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,352000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36590000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2442000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,622000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,622000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3064000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3066000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3066000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3066000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,46336430.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.07
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,48225041.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.06
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43800000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q1,2018-01-01,2018-03-31,2019-05-03 07:02:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.07
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,47350000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,47350000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5213000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5213000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,42137000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,27960000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9866000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,398000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38224000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3913000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,788000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,788000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4701000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,90000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4611000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4611000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4611000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52172982.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.09
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53945640.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.09
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q2,2018-04-01,2018-06-30,2019-08-01 07:04:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.09
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,49135000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,49135000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5068000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5068000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,44067000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26047000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11390000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,397000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37834000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6233000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1030000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1030000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7263000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,100000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7163000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7171000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52389012.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.14
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54709749.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.13
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51200000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q3,2018-07-01,2018-09-30,2019-11-07 07:03:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.14
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,53041000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,53041000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5667000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5667000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,47374000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,24922000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12922000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,380000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38224000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9150000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1168000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1168000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,10318000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-50000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10368000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10360000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10360000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50859947.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.2
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53045257.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.2
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.2
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59060000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59060000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6368000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6368000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,52692000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,31468000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10950000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,42818000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9895000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1649000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1649000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,11544000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,18000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11526000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,11526000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,11526000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53101499.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54579982.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.21
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q2,2019-04-01,2019-06-30,2019-08-01 07:04:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,59485000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,59485000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6782000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6782000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,52703000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,30221000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11347000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,376000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41944000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10759000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1517000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1517000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12276000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-88147000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,100423000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,100423000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,100423000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53297298.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.88
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54541625.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.84
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53400000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q3,2019-07-01,2019-09-30,2019-11-07 07:03:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.88
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,60930000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,60930000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6225000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6225000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,54705000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,37018000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13074000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,329000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,20000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,50441000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4243000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1567000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1567000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5810000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1594000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4216000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4216000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4216000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53137562.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,54847060.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53300000.0
Vanda Pharmaceuticals Inc,VNDA,,0001347178,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.08
